Differential expression of the angiotensin-(1-12)/chymase axis in human atrial tissue

Therapeutic Advances in Cardiovascular Disease

Volumn 9, Issue 4, 2015, Pages 168-180

  Nagata, Sayaka ^a   Simington, Stephen W ^a   Ahmad, Sarfaraz ^a   Voncannon, Jessica L ^a   Varagic, Jasmina ^a   Kon, Neal D ^a   Deal, Dwight ^a   Wang, Hao ^a   Groban, Leanne ^a   Dell’italia, Louis J ^b   Ferrario, Carlos M ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b BIRMINGHAM VA MEDICAL CENTER   (United States)

Author keywords

angiotensin converting enzyme inhibitors; angiotensin II; antihypertensive therapy; aortic valve disease; arrhythmia; cardiac chymase; coronary heart disease; enzymes; heart surgery

Indexed keywords

ANGIOTENSIN DERIVATIVE; ANGIOTENSINOGEN; ANGIOTENSIN[1-12]; ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; CHYMASE; MESSENGER RNA; NEUROPEPTIDE Y; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG; ANGIOTENSIN I; ANGIOTENSIN II;

ADULT; ANTIBODY AFFINITY; AORTIC VALVE REPAIR; ARTICLE; ATRIAL FIBRILLATION; CARDIOVASCULAR PARAMETERS; CELL MEMBRANE; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; ECHOCARDIOGRAPHY; ENZYME ACTIVITY; FEMALE; GENETIC TRANSCRIPTION; HEART ATRIUM; HEART ATRIUM APPENDAGE; HEART LEFT ATRIUM; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART LEFT VENTRICLE ENDSYSTOLIC VOLUME; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; INTERVENTRICULAR SEPTUM; ISCHEMIC HEART DISEASE; LEFT VENTRICULAR POSTERIOR WALL; MALE; MITRAL VALVE REPAIR; NEUROTRANSMISSION; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RIGHT ATRIUM APPENDAGE; VALVULAR HEART DISEASE; AGED; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; HEART VALVE DISEASES; HEART VENTRICLE REMODELING; METABOLISM; MIDDLE AGED; MYOCARDIAL ISCHEMIA; UPREGULATION;

AGED; ANGIOTENSIN I; ANGIOTENSIN II; ANGIOTENSINOGEN; ATRIAL FIBRILLATION; CHYMASES; ECHOCARDIOGRAPHY; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HEART ATRIA; HEART VALVE DISEASES; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; RNA, MESSENGER; UP-REGULATION; VENTRICULAR REMODELING;

EID: 84940865762     PISSN: 17539447     EISSN: 17539455     Source Type: Journal    
DOI: 10.1177/1753944715589717     Document Type: Article

References (56)

1. Ahmad S. Simmons T. Varagic J. Moniwa N. Chappell M. Ferrario C. (2011 a) Chymase-dependent generation of angiotensin II from angiotensin-(1–12) in human atrial tissue. PloS ONE 6: e28501.
2. Ahmad S. Varagic J. Westwood B. Chappell M. Ferrario C. (2011 b) Uptake and metabolism of the novel peptide angiotensin-(1–12) by neonatal cardiac myocytes. PloS ONE 6: e15759.
3. Ahmad S. Wei C. Tallaj J. Dell’italia L. Moniwa N. Varagic J. et al (2013) Chymase mediates angiotensin-(1–12) metabolism in normal human hearts. J Am Soc Hypertens 7: 128–136.
4. Arizono N. Matsuda S. Hattori T. Kojima Y. Maeda T. Galli S. (1990) Anatomical variation in mast cell nerve associations in the rat small intestine, heart, lung, and skin. Similarities of distances between neural processes and mast cells, eosinophils, or plasma cells in the jejunal lamina propria. Lab Invest 62: 626–634.
5. Bainbridge F. (1915) The influence of venous filling upon the rate of the heart. J Physiol 50: 65–84.
6. Baker K. Booz G. Dostal D. (1992) Cardiac actions of angiotensin II: Role of an intracardiac renin-angiotensin system. Ann Rev Physiol 54: 227–241.
7. Baker K. Chernin M. Schreiber T. Sanghi S. Haiderzaidi S. Booz G. et al (2004) Evidence of a novel intracrine mechanism in angiotensin II-induced cardiac hypertrophy. Regul Pept 120: 5–13.
8. Baker K. Kumar R. (2006) Intracellular angiotensin II induces cell proliferation independent of AT 1 receptor. Am J Physiol Cell Physiol 291: C995–C1001.
9. Balcells E. Meng Q. Johnson W. Jr. Oparil S. Dell’italia L. (1997) Angiotensin II formation from ACE and chymase in human and animal hearts: methods and species considerations. Am J Physiol 273: H1769–H1774.
10. Cingolani H. Perez N. Cingolani O. Ennis I. (2013) The Anrep effect: 100 years later. Am J Physiol Heart Circ Physiol 304: H175–H182.
11. Cox J. Boineau J. Schuessler R. Kater K. Lappas D. (1993) Five-year experience with the MAZE procedure for atrial fibrillation. Ann Thorac Surg 56: 814–823.
12. Crystal G. Salem M. (2012) The Bainbridge and the “reverse” Bainbridge reflexes: history, physiology, and clinical relevance. Anesth Analg 114: 520–532.
13. de Mello W. Danser A. (2000) Angiotensin II and the heart : on the intracrine renin-angiotensin system. Hypertension 35: 1183–1188.
14. Dell’italia L. Husain A. (2002) Dissecting the role of chymase in angiotensin II formation and heart and blood vessel diseases. Curr Opin Cardiol 17: 374–379.
15. Disertori M. Barlera S. Staszewsky L. Latini R. Quintarelli S. Franzosi M. (2012) Systematic review and meta-analysis: renin-Angiotensin system inhibitors in the prevention of atrial fibrillation recurrences: an unfulfilled hope. Cardiovasc Drugs Ther 26: 47–54.
16. Dostal D. Baker K. (1999) The cardiac renin-angiotensin system: conceptual, or a regulator of cardiac function? Circ Res 85: 643–650.
17. Ennezat P. Berlowitz M. Sonnenblick E. Le Jemtel T. (2000) Therapeutic implications of escape from angiotensin-converting enzyme inhibition in patients with chronic heart failure. Curr Cardiol Rep 2: 258–262.
18. Ferrario C. Ahmad S. Nagata S. Simington S. Varagic J. Kon N. et al (2014) An evolving story of angiotensin-II-forming pathways in rodents and humans. Clin Sci 126: 461–469.
19. Ferrario C. Jessup J. Chappell M. Averill D. Brosnihan K. Tallant E. et al (2005 a) Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation 111: 2605–2610.
20. Ferrario C. Trask A. Jessup J. (2005 b) Advances in biochemical and functional roles of angiotensin-converting enzyme 2 and angiotensin-(1–7) in regulation of cardiovascular function. Am J Physiol Heart Circ Physiol 289: H2281-H2290.
21. Ferrario C. Varagic J. Habibi J. Nagata S. Kato J. Chappell M. et al (2009) Differential regulation of angiotensin-(1–12) in plasma and cardiac tissue in response to bilateral nephrectomy. Am J Physiol Heart Circ Physiol 296: H1184-H1192.
22. Gollob M. Jones D. Krahn A. Danis L. Gong X. Shao Q. et al (2006) Somatic mutations in the connexin 40 gene (GJA5) in atrial fibrillation. N Engl J Med 354: 2677–2688.
23. Haissaguerre M. Jais P. Shah D. Takahashi A. Hocini M. Quiniou G. et al (1998) Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med 339: 659–666.
24. Huang X. Chen W. Truong L. Lan H. (2003) Chymase is upregulated in diabetic nephropathy: implications for an alternative pathway of angiotensin II-mediated diabetic renal and vascular disease. J Am Soc Nephrol 14: 1738–1747.
25. Jessup J. Trask A. Chappell M. Nagata S. Kato J. Kitamura K. et al (2008) Localization of the novel angiotensin peptide, angiotensin-(1–12), in heart and kidney of hypertensive and normotensive rats. Am J Physiol Heart Circ Physiol 294: H2614-H2618.
26. Kahr P. Piccini I. Fabritz L. Greber B. Scholer H. Scheld H. et al (2011) Systematic analysis of gene expression differences between left and right atria in different mouse strains and in human atrial tissue. PloS ONE 6: e26389.
27. Kienzle M. Ferguson D. Birkett C. Myers G. Berg W. Mariano D. (1992) Clinical, hemodynamic and sympathetic neural correlates of heart rate variability in congestive heart failure. Am J Cardiol 69: 761–767.
28. Kumar R. Thomas C. Yong Q. Chen W. Baker K. (2012) The intracrine renin-angiotensin system. Clin Sci 123: 273–284.
29. Kuncova J. Sviglerova J. Tonar Z. Slavikova J. (2005) Heterogenous changes in neuropeptide Y, norepinephrine and epinephrine concentrations in the hearts of diabetic rats. Auton Neurosci 121: 7–15.
30. Laight D. (2009) Therapeutic inhibition of the renin angiotensin aldosterone system. Expert Opin Ther Pat 19: 753–759.
31. Lang R. Bierig M. Devereux R. Flachskampf F. Foster E. Pellikka P. et al (2005) Recommendations for chamber quantification: a report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 18: 1440–1463.
32. Linz D. Ukena C. Mahfoud F. Neuberger H. Bohm M. (2014) Atrial autonomic innervation: a target for interventional antiarrhythmic therapy? J Am Coll Cardiol 63: 215–224.
33. Malliani A. Montano N. (2004) Sympathetic overactivity in ischaemic heart disease. Clin Sci 106: 567–568.
34. Mehta R. Supiano M. Oral H. Grossman P. Montgomery D. Smith M. et al (2003) Compared with control subjects, the systemic sympathetic nervous system is activated in patients with mitral regurgitation. Am Heart J 145: 1078–1085.
35. Mehta R. Supiano M. Oral H. Grossman P. Petrusha J. Montgomery D. et al (2000) Relation of systemic sympathetic nervous system activation to echocardiographic left ventricular size and performance and its implications in patients with mitral regurgitation. Am J Cardiol 86: 1193–1197.
36. Melendez G. Li J. Law B. Janicki J. Supowit S. Levick S. (2011) Substance P induces adverse myocardial remodelling via a mechanism involving cardiac mast cells. Cardiovasc Res 92: 420–429.
37. Moniwa N. Varagic J. Simington S. Ahmad S. Nagata S. Voncannon J. et al (2013) Primacy of angiotensin converting enzyme in angiotensin-(1–12) metabolism. Am J Physiol Heart Circ Physiol 305: H644-H650.
38. Nagata S. Kato J. Kuwasako K. Kitamura K. (2010) Plasma and tissue levels of proangiotensin-12 and components of the renin-angiotensin system (RAS) following low- or high-salt feeding in rats. Peptides 31: 889–892.
39. Nagata S. Kato J. Sasaki K. Minamino N. Eto T. Kitamura K. (2006) Isolation and identification of proangiotensin-12, a possible component of the renin-angiotensin system. Biochem Biophys Res Commun 350: 1026–1031.
40. Onuoha G. Nicholls D. Alpar E. Ritchie A. Shaw C. Buchanan K. (1999) Regulatory peptides in the heart and major vessels of man and mammals. Neuropeptides 33: 165–172.
41. Pardini B. Lund D. Puk D. (1992) Sites at which neuropeptide Y modulates parasympathetic control of heart rate in guinea pigs and rats. J Auton Nerv Syst 38: 139–145.
42. Park S. Bivona B. Ford S. Jr. Xu S. Kobori H. de Garavilla L. et al (2013) Direct evidence for intrarenal chymase-dependent angiotensin II formation on the diabetic renal microvasculature. Hypertension 61: 465–471.
43. Prosser H. Forster M. Richards A. Pemberton C. (2009) Cardiac chymase converts rat proAngiotensin-12 (PA12) to angiotensin II: effects of PA 12 upon cardiac haemodynamics. Cardiovasc Res 82: 40–50.
44. Re R. Cook J. (2011) Noncanonical intracrine action. J Am Soc Hypertens 5: 435–448.
45. Ries P. Fuder H. (1994) Differential effects on sympathetic neurotransmission of mast cell degranulation by compound 48 / 80 or antigen in the rat isolated perfused heart. Methods Find Exp Clin Pharmacol 16: 419–435.
46. Ritz E. (2003) Chymase: a potential culprit in diabetic nephropathy? J Am Soc Nephrol 14: 1952–1954.
47. Schomig A. Haass M. Richardt G. (1991) Catecholamine release and arrhythmias in acute myocardial ischaemia. Eur Heart J 12(Suppl. F): 38–47.
48. Singh V. Baker K. Kumar R. (2008) Activation of the intracellular renin-angiotensin system in cardiac fibroblasts by high glucose: role in extracellular matrix production. Am J Physiol Heart Circ Physiol 294: H1675–H1684.
49. Tokuyama H. Hayashi K. Matsuda H. Kubota E. Honda M. Okubo K. et al (2002) Differential regulation of elevated renal angiotensin II in chronic renal ischemia. Hypertension 40: 34–40.
50. Trask A. Jessup J. Chappell M. Ferrario C. (2008) Angiotensin-(1–12) is an alternate substrate for angiotensin peptide production in the heart. Am J Physiol Heart Circ Physiol 294: H2242–H2247.
51. Turnbull F. Neal B. Algert C. Chalmers J. Chapman N. Cutler J. et al (2005) Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch Intern Med 165: 1410–1419.
52. Turnbull F. Neal B. Ninomiya T. Algert C. Arima H. Barzi F. et al (2008) Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials. Br Med J 336: 1121–1123.
53. Turnbull F. Neal B. Pfeffer M. Kostis J. Algert C. Woodward M. et al (2007) Blood pressure-dependent and independent effects of agents that inhibit the renin-angiotensin system. J Hypertens 25: 951–958.
54. van den Meiracker A. Man in ‘t Veld A. Admiraal P. Ritsema van Eck H. Boomsma F. Derkx F. et al (1992) Partial escape of angiotensin converting enzyme (ACE) inhibition during prolonged ACE inhibitor treatment: does it exist and does it affect the antihypertensive response? J Hypertens 10: 803–812.
55. Wei C. Tian B. Perry G. Meng Q. Chen Y. Oparil S. et al (2002) Differential ANG II generation in plasma and tissue of mice with decreased expression of the ACE gene. Am J Physiol Heart Circ Physiol 282: H2254–H2258.
56. Yang B. Phillips M. Ambuehl P. Shen L. Mehta P. Mehta J. (1997) Increase in angiotensin II type 1 receptor expression immediately after ischemia-reperfusion in isolated rat hearts. Circulation 96: 922–926.